Insider Trading Activity Syros Pharmaceuticals Inc – Director Bought 109,774 shares of Stock

18

Insider Trading Activity For Syros Pharmaceuticals Inc

Srinivas Akkaraju , Director of Syros Pharmaceuticals Inc reportedly Bought 109,774 shares of the company’s stock at an average price of 9.03 for a total transaction amount of $991,259.22 SEC Form

Insider Trading History For Syros Pharmaceuticals Inc

  • On 7/6/2016 Robert Nelsen, Director, bought 400,000 with an average share price of $12.50 per share and the total transaction amounting to $5,000,000.00.View SEC Filing
  • On 7/6/2016 Redmile Group, Llc, Major Shareholder, bought 432,746 with an average share price of $12.50 per share and the total transaction amounting to $5,409,325.00.View SEC Filing
  • On 7/25/2017 Richard A Young, Director, sold 3,282 with an average share price of $22.09 per share and the total transaction amounting to $72,499.38.View SEC Filing
  • On 7/25/2017 Eric R Olson, Insider, sold 12,500 with an average share price of $21.85 per share and the total transaction amounting to $273,125.00.View SEC Filing
  • On 8/7/2017 Eric R Olson, Insider, sold 2,500 with an average share price of $23.59 per share and the total transaction amounting to $58,975.00.View SEC Filing
  • On 8/14/2017 Richard A Young, Director, sold 3,282 with an average share price of $22.00 per share and the total transaction amounting to $72,204.00.View SEC Filing
  • On 10/23/2017 Colleen Elizabeth Desimone, Insider, sold 550 with an average share price of $16.06 per share and the total transaction amounting to $8,833.00.View SEC Filing
  • Analyst Ratings History For Syros Pharmaceuticals Inc

    • On 9/9/2016 HC Wainwright Reiterated Rating Hold with a price target of $10.00
    • On 8/10/2017 Wedbush Reiterated Rating Outperform with a price target of $25.00 to $22.84
    • On 8/21/2017 Cann Reiterated Rating Buy with a price target of $28.00
    • On 9/28/2017 JMP Securities Upgraded rating Market Perform to Outperform with a price target of $33.00
    • On 10/23/2017 Roth Capital Initiated Coverage of rating Neutral to Neutral with a price target of $15.00
    • On 10/31/2017 Piper Jaffray Companies Reiterated Rating Overweight to Overweight with a price target of $30.00
    • On 12/11/2017 Cowen Reiterated Rating Buy

    Recent Trading Activity for Syros Pharmaceuticals Inc
    Shares of Syros Pharmaceuticals Inc closed the previous trading session at with shares trading hands.

    An ad to help with our costs